Stock comparison
Halozyme Therapeutics
STERIS
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
STE
STERIS
Market cap
$21.26B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | STE | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 53C | HALO |
| Benjamin Graham | 83A | 68B | HALO |
| Philip Fisher | 65B | 58C | HALO |
| Peter Lynch | 53D | 52C | HALO |
| Joel Greenblatt | 40D | 35D | HALO |
| Charlie Munger | 80C | 42D | HALO |
| Terry Smith | 84A | 48D | HALO |
Side-by-side metrics
| Metric | HALO | STE |
|---|---|---|
| Market cap | $8.1B | $21.26B |
| P/E (TTM) | 24.0x | 25.3x |
| EV/EBIT | 10.2x | 17.7x |
| ROIC (TTM) | 23.65% | 8.51% |
| Gross margin | 81.24% | 44.25% |
| Net margin | 23.13% | 13.18% |
| Revenue CAGR 5y | 33.23% | 8.88% |
| EPS CAGR 5y | -1.98% | 33.45% |
| Debt / Equity | 1.0x | 0.0x |
| Dividend yield | 0.0% | 1.22% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 8.88%+73%
- ROIC (TTM)23.65%vs 8.51%+64%
- Gross margin81.24%vs 44.25%+46%
- Net margin23.13%vs 13.18%+43%
STE leads on
- EPS CAGR 5y33.45%vs -1.98%+106%
- Dividend yield1.22%vs 0.0%+100%
- Debt / Equity0.0xvs 1.0x+98%
- Market cap$21.26Bvs $8.1B+62%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.